Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.27 Insider Own0.40% Shs Outstand219.83M Perf Week4.41%
Market Cap936.48M Forward P/E- EPS next Y-0.37 Insider Trans3.41% Shs Float218.70M Perf Month1.67%
Income-58.40M PEG- EPS next Q-0.12 Inst Own48.30% Short Float19.65% Perf Quarter-7.99%
Sales29.70M P/S31.53 EPS this Y80.00% Inst Trans-0.09% Short Ratio10.29 Perf Half Y-36.04%
Book/sh0.47 P/B9.06 EPS next Y-15.60% ROA-17.50% Target Price6.57 Perf Year-5.33%
Cash/sh1.00 P/C4.27 EPS next 5Y- ROE-54.10% 52W Range3.26 - 7.97 Perf YTD-27.18%
Dividend- P/FCF- EPS past 5Y51.20% ROI-13.90% 52W High-47.05% Beta-0.41
Dividend %- Quick Ratio3.80 Sales past 5Y52.70% Gross Margin80.50% 52W Low29.45% ATR0.19
Employees310 Current Ratio4.00 Sales Q/Q-81.40% Oper. Margin- RSI (14)56.73 Volatility3.90% 5.31%
OptionableYes Debt/Eq0.70 EPS Q/Q-83.30% Profit Margin- Rel Volume1.07 Prev Close4.26
ShortableYes LT Debt/Eq0.68 EarningsOct 27 Payout- Avg Volume4.18M Price4.22
Recom2.80 SMA205.84% SMA504.17% SMA200-24.36% Volume573,702 Change-0.94%
07-Aug-14Reiterated WallachBeth Buy $9 → $8
15-Nov-13Initiated WallachBeth Buy $9
03-Oct-13Initiated Cowen Market Perform $4.50
25-Oct-10Reiterated Barclays Capital Underweight $3 → $2
20-Sep-10Reiterated UBS Neutral $7 → $2
17-Sep-10Downgrade Davenport Buy → Neutral
14-Sep-10Downgrade Barclays Capital Equal Weight → Underweight $4 → $3
23-Aug-10Reiterated UBS Neutral $3.50 → $7
16-Jul-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1
02-Jul-10Reiterated UBS Buy $40 → $38
04-Feb-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
17-Dec-09Initiated Jefferies & Co Hold $4
21-Sep-09Downgrade Leerink Swann Outperform → Mkt Perform $6
18-Sep-09Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $3
15-Sep-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
18-Aug-09Initiated JMP Securities Mkt Perform
24-Jun-09Initiated Rodman & Renshaw Mkt Outperform $9
16-Mar-09Downgrade Canaccord Adams Hold → Sell
18-Feb-09Downgrade UBS Buy → Neutral $6 → $7
18-Feb-09Downgrade UBS Buy → Neutral
30-Oct-14 09:19AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
29-Oct-14 07:30AM  Arena Skimps on Data Disclosure From Weight-Loss Combo Study at TheStreet
28-Oct-14 06:20PM  Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot Study of Coadministration of Lorcaserin HCl and Phentermine HCl PR Newswire
27-Oct-14 08:00AM  Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3 PR Newswire
20-Oct-14 04:58PM  Bank Of America Q3 Small & Mid-Cap Biotech Preview Benzinga
13-Oct-14 08:00AM  Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College of Clinical Pharmacy Annual Meeting PR Newswire
10-Oct-14 11:36AM  Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine PR Newswire
09-Oct-14 04:41PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ EDGAR Online
02-Oct-14 12:10PM  Zafgen Aims Obesity Drug At Rare, Deadly Disease at Forbes
30-Sep-14 10:37AM  [video] Zafgen CEO: 2015 Will Be Data Rich Year for Obesity Treatment at TheStreet
22-Sep-14 08:00AM  Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference PR Newswire
19-Sep-14 06:43AM  Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% Zacks
16-Sep-14 09:48AM  Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy at TheStreet
11-Sep-14 05:15PM  [video] Orexigen drops in spite of FDA approval at CNBC
04:00PM  U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Reuters
01:23PM  Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised at TheStreet
08:37AM  Pharmalot, Pharmalittle: We're Reading About Orexigen, Allergan and Lots More!! at The Wall Street Journal
07:18AM  FDA approves weight-loss drug Contrave AP
10-Sep-14 09:16PM  New Drug to Treat Obesity Gains Approval by F.D.A. at New York Times
07:58PM  FDA Approves Contrave Weight Loss Drug From Orexigen And Takeda at Forbes
07:00PM  Orexigen Wins U.S. FDA Approval for Weight-Loss Pill at Bloomberg
08:00AM  Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium PR Newswire
09-Sep-14 09:32AM  FDA staff: Novo Nordisk drug liraglutide effective for obesity Reuters
03-Sep-14 04:20PM  Arena Pharmaceuticals' APD811 Gets Orphan Drug Status Zacks
11:50AM  Credit Suisse Positive on Some Biotechs, Very Cautious on Others at 24/7 Wall St.
02-Sep-14 08:00AM  Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension PR Newswire
19-Aug-14 10:45AM  You've got obesity all wrong: Zafgen CEO at CNBC
18-Aug-14 06:26AM  [video] Obesity treatment sales fall short at CNBC
15-Aug-14 01:04PM  ARENA PHARMACEUTICALS INC Financials EDGAR Online Financials
06-Aug-14 04:34PM  ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
04-Aug-14 10:10AM  Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss Zacks
01-Aug-14 08:18AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
07:07AM  Q2 2014 Arena Pharmaceuticals Earnings Release - After Market Close CCBN
04:30AM  Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results PR Newswire
31-Jul-14 06:00AM  'Mad Money' Lightning Round: Stay With Thermo Fisher Scientific at TheStreet
30-Jul-14 08:00AM  Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity PR Newswire
29-Jul-14 08:00AM  Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category PR Newswire
25-Jul-14 03:51PM  Arena Sees Belviq Sales Climb Despite Seasonality at Seeking Alpha
08:00AM  Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 PR Newswire
21-Jul-14 04:33PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
08:11AM  Arena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary theflyonthewall.com
08:00AM  Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) in Israel PR Newswire
19-Jul-14 04:14PM  The Implications of Obesity as a Disability in Europe at Motley Fool
18-Jul-14 02:10PM  Arena Stock Rises With Expected Jump In Belviq Sales at Seeking Alpha
16-Jul-14 03:30PM  Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent Zacks
11:20AM  Arena Gives Pipeline Exposure - Is The Company Partner Shopping? at Seeking Alpha
15-Jul-14 06:50PM  Arena Pharmaceuticals Inc. Still Down After CEO's Sale at Motley Fool
04:34PM  Arena Pharmaceuticals granted patent for Cannabinoid Receptor Modulators theflyonthewall.com
04:31PM  Arena Pharmaceuticals Issued Patent for APD371 by United States Patent and Trademark Office PR Newswire
01:10PM  Fed Chair Yellen Says Small Biotech Stocks Over-Valued at TheStreet
14-Jul-14 12:13PM  Perilous Reversal Watch: Arena Pharmaceuticals (ARNA) at TheStreet
11-Jul-14 03:45PM  Arena Pharmaceuticals-Eisai Boost Obesity Drug Sales Force Zacks +6.13%
01:01PM  Arena Stock Holds On Expected Dip In Sales - Bottom May Be In at Seeking Alpha
10-Jul-14 08:56AM  Top Biotech Stocks to Watch Today: Allergan, Arena Pharmaceuticals and Bristol-Myers Squibb at Motley Fool
08:00AM  Arena Pharmaceuticals Reports that Eisai Completes Planned Increase in Sales Force for BELVIQ® (lorcaserin HCl) CIV PR Newswire
08-Jul-14 06:45AM  Arena Pharmaceuticals (ARNA) in Focus: Stock Slumps 9.4% Zacks -5.29%
07-Jul-14 04:37PM  Arena Prescription Sales OK - CEO Sales Are Not at Seeking Alpha -9.42%
04:37PM  Markets Marginally Lower Ahead Of Earnings Season Benzinga
04:20PM  On The Fly: Closing Wrap at theflyonthewall.com
01:58PM  Why Arena Pharmaceuticals (ARNA) Stock Is Dropping Today at TheStreet
12:45PM  Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His Shares Benzinga
11:23AM  Arena CEO Dumps Stock as Share Price, Investor Confidence Slide at TheStreet
11:00AM  Insider Trading Alert - SFLY, ARNA And ENS Traded By Insiders at TheStreet
09:16AM  On The Fly: Pre-market Movers at theflyonthewall.com
01-Jul-14 05:53PM  Arena Needs To Hold Eisai Accountable For Re-Launch Of Belviq at Seeking Alpha
27-Jun-14 05:30PM  Are Investors Wrong About Orexigen Therapeutics?
12:37PM  Arena's Belviq Sales Flat Again at Seeking Alpha
25-Jun-14 05:30PM  Are Investors Wrong About VIVUS?
24-Jun-14 06:20AM  How Bad Is This Delay for Orexigen Therapeutics, Inc?
22-Jun-14 05:31PM  FDA Drops the Hammer on Twitter at Motley Fool
20-Jun-14 04:30PM  Belviq Sales Flat - Is Seasonality Coming Into Play? at Seeking Alpha
11:34AM  The Anti-Obesity Space Is Not As Simple As Some Think at Seeking Alpha
19-Jun-14 03:12PM  Why Zafgen Inc. Shares Roared Higher at Motley Fool
16-Jun-14 04:19PM  What Will It Take For Arena Stock To Rise? at Seeking Alpha
13-Jun-14 05:23PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
02:49PM  Arena's Belviq Sales Do More Than Recover at Seeking Alpha
08:00AM  Arena Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference PR Newswire
12-Jun-14 08:28AM  Today's Top Biotech Stocks to Watch: Geron Corporation and Arena Pharmaceuticals at Motley Fool
05:00AM  'Fast Money' Recap: Reacting to Today's Headlines at TheStreet
11-Jun-14 05:28PM  [video] Losing weight with Arena Pharmaceuticals CEO at CNBC
05:07PM  Why Orexigen Therapeutics Inc. Shares Were Throttled at Motley Fool
02:15PM  Is Arena Pharmaceuticals A Biotech Stock To Watch? Benzinga
02:11PM  Why Orexigen Therapeutics is Falling Today at Motley Fool
11:55AM  Orexigen Obesity Drug Decision Delayed By FDA at Investor's Business Daily
11:34AM  Down 18%: Is Orexigen a Bad News Buy? at Motley Fool
08:21AM  Ahead of the Bell: Orexigen Therapeutics slips AP
10-Jun-14 01:22PM  Orexigen Investors Hope For FDA Approval at Seeking Alpha
11:22AM  Fat Chance? Betting On Whether the Orexigen Diet Drug Expands a Slim Market at The Wall Street Journal
09-Jun-14 06:02PM  Does Wall Street Still Hate Arena Pharmaceuticals? at Motley Fool
05:22PM  Orexigen Could Be A Double-Edged Sword For Arena at Seeking Alpha
02:06PM  As Orexigen Faces FDA Will Weight Loss Landscape Change? at Motley Fool
01:39PM  [video] Expectations for new obesity drug at CNBC
12:45PM  Third time's a charm for Orexigen's obesity drug? at CNBC
12:45PM  Orexigen may give diet pill market the jolt it needs at CNBC
12:45PM  Obesity game-changer? Why this time it's different at CNBC
12:45PM  Obesity game changer? Why this time it's different at CNBC
12:43PM  Orexigen: 'Goldilocks' Obesity Pill Awaits FDA Approval Decision Wednesday at TheStreet
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company's products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug products under a manufacturing services agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LIEF JACKChairman, President and CEOSep 17Option Exercise1.49100,000149,000441,039Sep 19 04:50 PM
LIEF JACKChairman, President and CEOJul 01Sale5.85223,5251,308,582361,039Jul 03 04:38 PM
BELCHER DONALD DDirectorJun 27Option Exercise5.462,47313,50396,585Jun 27 06:49 PM
BELCHER DONALD DDirectorJun 27Sale5.852,47314,46794,112Jun 27 06:49 PM
SPECTOR STEVEN WEVP, General Counsel & SecMay 12Option Exercise1.4945,00067,050147,187May 14 07:34 PM
SPECTOR STEVEN WEVP, General Counsel & SecMay 12Sale7.0545,000317,358102,187May 14 07:34 PM
BELCHER DONALD DDirectorMay 06Option Exercise4.314,17617,99972,904May 07 07:54 PM
BELCHER DONALD DDirectorMay 06Sale7.004,17629,23268,728May 07 07:54 PM
HIXSON HARRY F JRDirectorApr 22Option Exercise4.1136,900151,659119,776Apr 24 06:14 PM
HIXSON HARRY F JRDirectorApr 22Sale6.3136,900232,75482,876Apr 24 06:14 PM
Nova Tina SusanDirectorApr 14Option Exercise4.7035,000164,35053,728Apr 15 09:59 PM
Nova Tina SusanDirectorApr 14Sale6.2235,000217,76318,728Apr 15 09:59 PM
BELCHER DONALD DDirectorApr 01Option Exercise6.301,90512,00270,633Apr 02 08:34 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerApr 01Option Exercise6.3060,000378,00095,000Apr 02 08:35 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerApr 01Sale6.3760,000382,01435,000Apr 02 08:35 PM
BELCHER DONALD DDirectorApr 01Sale6.451,90512,28768,728Apr 02 08:34 PM
SPECTOR STEVEN WEVP, General Counsel & SecMar 04Option Exercise1.4925,00037,250126,794Mar 05 08:03 PM
SPECTOR STEVEN WEVP, General Counsel & SecMar 04Sale7.0125,000175,250101,794Mar 05 08:03 PM
LIEF JACKChairman, President and CEOJan 17Option Exercise6.00100,000600,000683,704Jan 17 07:18 PM
LIEF JACKChairman, President and CEOJan 17Sale7.81100,000781,260583,704Jan 17 07:18 PM
BEHAN DOMINIC PEVP & Chief Scientific OfficerJan 10Option Exercise6.0033,332199,992516,332Jan 13 08:43 PM
BEHAN DOMINIC PEVP & Chief Scientific OfficerJan 10Sale6.2533,332208,325483,000Jan 13 08:43 PM
SPECTOR STEVEN WEVP, General Counsel & SecJan 09Option Exercise6.0033,334200,004135,128Jan 13 08:44 PM
BELCHER DONALD DDirectorJan 09Option Exercise6.0030,000180,00098,728Jan 13 08:45 PM
BICE SCOTT HDirectorJan 09Option Exercise6.0025,000150,00048,628Jan 13 08:46 PM
BICE SCOTT HDirectorJan 09Sale6.1025,000152,50023,628Jan 13 08:46 PM
BELCHER DONALD DDirectorJan 09Sale6.1530,000184,50068,728Jan 13 08:45 PM
SPECTOR STEVEN WEVP, General Counsel & SecJan 09Sale6.1033,334203,337101,794Jan 13 08:44 PM
SPECTOR STEVEN WEVP, General Counsel & SecNov 12Option Exercise1.4920,00029,80091,420Nov 13 07:46 PM
SPECTOR STEVEN WEVP, General Counsel & SecNov 12Sale5.1920,000103,71071,420Nov 13 07:46 PM